2 completed, 2 unknown, 1 withdrawn. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 2, Unknown 2, Withdrawn 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Agoraphobia: new trials by email Literature Review of Agoraphobia trials Research Report on Agoraphobia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study Cannabidiol (CBD) Oil Capsules, Sunflower Lecithin Oil in Capsule - Generalized Anxiety Disorder, Social Anxiety Disorder | Phase 3 | Unknown | McMaster University | 50 | 2021-12-15 | 2023-02-14 |
| Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study 50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose), Placebo Oil - Generalized Anxiety Disorder, Social Anxiety Disorder | Phase 3 | Withdrawn | McMaster University | 2021-04-01 | 2021-03-24 | |
| Mechanisms of Panic Disorders Treatment Cognitive Behavioural Therapy (CBT) - Panic Disorder, Agoraphobia | Phase 2 / Phase 3 | Unknown | University Medicine Greifswald | 180 | 2010-03-01 | 2011-04-11 |
| Comparison of Psychotherapy Programs to Treat Panic Disorder Cognitive behavioral therapy, Applied relaxation training (ART), Panic focused psychodynamic psychotherapy (PFPP) - Anxiety Disorders, Panic Disorder | Phase 3 | Completed | Weill Medical College of Cornell University | 201 | 2006-09-01 | 2022-12-23 |
| Treatment of Panic Disorder: Long Term Strategies Cognitive behavior therapy, Paroxetine or other medication - algorithm used - Panic Disorder, Agoraphobia | Phase 3 | Completed | New York State Psychiatric Institute | 379 | 1999-02-01 | 2014-03-18 |
Panic Disorder (5) · Anxiety Disorders (3) · Generalized Anxiety Disorder (2) · Marijuana Abuse (2) · Phobia, Social (2) · Recurrence (1)
Mental Disorders (5) · Phobic Disorders (5) · Anxiety Disorders (2) · Chemically-Induced Disorders (2) · Substance-Related Disorders (2) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Cognitive Behavioral Therapy (3) · Cannabidiol (1) · Capsules (1) · Exercise (1) · Oils (1) · Paroxetine (1)
McMaster University (2) · New York State Psychiatric Institute (1) · University Medicine Greifswald (1) · Weill Medical College of Cornell University (1)
Canada (2) · United States (2) · Germany (1)
Michael Van Ameringen, MD, FRCPC (2) · Alexander L. Gerlach, Prof. Dr. (1) · Alfons O. Hamm, Prof. Dr. (1) · Barbara Milrod, MD (1) · David H Barlow, PhD (1) · Georg W. Alpers, Prof. Dr. (1) · Jack Gorman, MD (1) · Jacques P. Barber, PhD (1) · Katherine H. Shear, MD (1) · Scott Woods, MD (1) · Thomas Lang, Dr. (1) · Tilo Kirchner, Prof. Dr. (1)
PMID 26663632, PMID 26877119, PMID 27235836, PMID 27464313, PMID 29336228, PMID 30256548, PMID 30341278, PMID 30718541, PMID 30773148, PMID 30821630, PMID 30869969, PMID 31712720, PMID 31734525, PMID 31838872, PMID 32105128, PMID 32584211, PMID 32734299
R01MH045963 (1), R01MH045964 (1), R01MH045965 (1), R01MH045966 (1), R01MH070664 (1)